Update on TNF Inhibitors in Dermatology.

Update on TNF Inhibitors in Dermatology. Semin Cutan Med Surg. 2016 Jun;35(6S):S104-S106 Authors: Sobell JM Abstract Emerging data describe new potential indications for tumor necrosis factor (TNF) inhibitors in dermatology, including pediatric psoriasis and hidradenitis suppurativa. New biosimilar TNF agents are in late stages of development and may be available in the United States in the near future. Biosimilar agents are similar but not identical to available TNF inhibitors, and approval requires extensive analytic, toxicity, pharmacokinetic, pharmacodynamic, and clinical testing. Semin Cutan Med Surg 35(supp6):S104-S106. PMID: 27537073 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27537073?dopt=Abstract

Source: Seminars in Cutaneous Medicine and Surgery - August 19, 2016 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research